Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard A. Furie, Michelle A. Petri, Marilyn C. Pike, Piotr Leszczyński, C. Michael Neuwelt, Kathryn Hobbs, Mauro Keiserman, Liliana Duca, Kenneth C. Kalunian, Catrinel Galateanu, Sabine Bongardt, Christian Stach, Carolyn Beaudot, Brian Kilgallen, Caroline Gordon
  • Arthritis & Rheumatology, January 2017, Wiley
  • DOI: 10.1002/art.39856

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Professor Antonio Fernandez-Nebro